PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16319604-3 2005 RESULTS: Dose-dependent inhibitory effects on vascular endothelisal growth factor production stimulated by hypoxia or tumor necrosis factor-alpha were noted in the groups treated with Clarithromycin and Roxisthromycin, including inhibition of vascular endothelisal growth factor mRNA levels. Clarithromycin 184-198 tumor necrosis factor Homo sapiens 118-145 28550735-0 2017 Clarithromycin inhibits TNF-alpha-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. Clarithromycin 0-14 tumor necrosis factor Homo sapiens 24-33 28550735-6 2017 Here, we demonstrate that the MKP-1 protein is induced by clarithromycin and that clarithromycin suppresses TNF-alpha-induced MUC5AC mucin gene expression in a p38 MAPK-dependent manner in human airway epithelial (NCI-H292) cells. Clarithromycin 82-96 tumor necrosis factor Homo sapiens 108-117 23199585-7 2013 CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05). Clarithromycin 0-3 tumor necrosis factor Homo sapiens 64-73 23199585-10 2013 CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production. Clarithromycin 0-3 tumor necrosis factor Homo sapiens 38-47 17069099-6 2006 RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo. Clarithromycin 140-154 tumor necrosis factor Homo sapiens 42-51 17069099-9 2006 CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing. Clarithromycin 12-26 tumor necrosis factor Homo sapiens 51-60 29093413-0 2018 Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFalpha Antibody in a Patient with Intestinal Behcet Disease. Clarithromycin 43-57 tumor necrosis factor Homo sapiens 71-79 25769240-9 2015 EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-alpha from NCI-H292 cells. Clarithromycin 7-10 tumor necrosis factor Homo sapiens 80-107 22564837-6 2012 The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group. Clarithromycin 112-126 tumor necrosis factor Homo sapiens 51-78 22564837-6 2012 The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group. Clarithromycin 112-126 tumor necrosis factor Homo sapiens 80-89 22564837-9 2012 The release of TNF-alpha, IL-6, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) by circulating monocytes after stimulation was greater in the clarithromycin group than in the placebo group. Clarithromycin 165-179 tumor necrosis factor Homo sapiens 15-24 22577246-5 2012 AZM or CAM significantly inhibited tumor necrosis factor-alpha (TNF-alpha) (20 ng/mL)-induced MUC5AC secretion from NCI-H292 cells at 10-6-10-7 M, whereas JM or ABPC showed no effect. Clarithromycin 7-10 tumor necrosis factor Homo sapiens 35-62 22577246-5 2012 AZM or CAM significantly inhibited tumor necrosis factor-alpha (TNF-alpha) (20 ng/mL)-induced MUC5AC secretion from NCI-H292 cells at 10-6-10-7 M, whereas JM or ABPC showed no effect. Clarithromycin 7-10 tumor necrosis factor Homo sapiens 64-73 21315154-4 2011 Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release. Clarithromycin 51-65 tumor necrosis factor Homo sapiens 165-174 15252191-3 2004 OBJECTIVE: To evaluate the antiinflammatory effect of clarithromycin on serum and sputum interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 levels in patients with COPD. Clarithromycin 54-68 tumor necrosis factor Homo sapiens 111-138 15252191-9 2004 After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001). Clarithromycin 120-134 tumor necrosis factor Homo sapiens 72-81 15252191-9 2004 After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001). Clarithromycin 120-134 tumor necrosis factor Homo sapiens 243-252 15252191-11 2004 CONCLUSIONS: This study demonstrated that the decrease in IL-8 and TNF-alpha levels might be related to the antiinflammatory effect of clarithromycin. Clarithromycin 135-149 tumor necrosis factor Homo sapiens 67-76 12065339-12 2002 However, the PCR-positive subjects who received clarithromycin demonstrated a reduction in TNF-alpha (p = 0.006), IL-5 (p = 0.007), and IL-12 (p = 0.004) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.0009). Clarithromycin 48-62 tumor necrosis factor Homo sapiens 170-179 14551160-7 2004 On the other hand, pretreatment of TNF-alpha-stimulated A549 cells by erythromycin, clarithromycin, azithromycin, or dexamethasone, but not josamycin, decreased the neutrophil survival-enhancing effects in a dose-dependent manner. Clarithromycin 84-98 tumor necrosis factor Homo sapiens 35-44 14551160-9 2004 Erythromycin, clarithromycin, azithromycin, and dexamethasone inhibited TNF-alpha-induced GM-CSF expression in A549 cells at both the protein and messenger RNA levels. Clarithromycin 14-28 tumor necrosis factor Homo sapiens 72-81 12065339-12 2002 However, the PCR-positive subjects who received clarithromycin demonstrated a reduction in TNF-alpha (p = 0.006), IL-5 (p = 0.007), and IL-12 (p = 0.004) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.0009). Clarithromycin 48-62 tumor necrosis factor Homo sapiens 91-100 12065339-13 2002 The PCR-negative subjects who received clarithromycin only demonstrated a reduction in TNF-alpha (p = 0.01) and IL-12 (p = 0.002) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.004). Clarithromycin 39-53 tumor necrosis factor Homo sapiens 87-96 12065339-13 2002 The PCR-negative subjects who received clarithromycin only demonstrated a reduction in TNF-alpha (p = 0.01) and IL-12 (p = 0.002) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.004). Clarithromycin 39-53 tumor necrosis factor Homo sapiens 146-155 12760488-9 2001 Examination showed that initially clarithromycin treatment triggered the release of NO, H2O2, IL-1 and TNFalpha from the monocytes, known mediators of inflammation, but also mediators which cause bacterial cell death or apoptosis. Clarithromycin 34-48 tumor necrosis factor Homo sapiens 103-111 11120942-4 2001 Flow cytometry revealed that clarithromycin suppresses NF-kappaB activation induced by TNF-alpha in U-937 and Jurkat cells in a concentration-related manner. Clarithromycin 29-43 tumor necrosis factor Homo sapiens 87-96 11120942-5 2001 Western blot analysis also demonstrated that clarithromycin inhibits NF-kappaB activation induced by TNF-alpha in U-937, Jurkat, and A549 cells and PBMC and by SEA in PBMC. Clarithromycin 45-59 tumor necrosis factor Homo sapiens 101-110 35440370-6 2022 The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038). Clarithromycin 31-45 tumor necrosis factor Homo sapiens 146-155 10615065-8 2000 TNF-alpha-induced promoter activity in this segment showed a significant repression by CAM. Clarithromycin 87-90 tumor necrosis factor Homo sapiens 0-9 10615065-11 2000 In accord with promoter analyses, an electrophoretic mobility shift assay showed that CAM repressed AP-1 binding in TNF-alpha-treated BET-1A cells; however, TNF-alpha induced both AP-1 and NF-kappaB binding activities in BET-1A cells. Clarithromycin 86-89 tumor necrosis factor Homo sapiens 116-125 10930442-6 2000 Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity. Clarithromycin 65-79 tumor necrosis factor Homo sapiens 99-108 10930442-6 2000 Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity. Clarithromycin 81-84 tumor necrosis factor Homo sapiens 99-108 10221415-5 1999 The results with IL-6 and TNF-alpha in the clarithromycin studies were most striking. Clarithromycin 43-57 tumor necrosis factor Homo sapiens 26-35